Frank Torti - 23 May 2024 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Reporting relationship: Director
Issuer ticker: ABUS
Reported as of: 23 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 May 2024, 16:07:10 UTC
Prior SEC filing: 04 Apr 2024
Next SEC filing: 03 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ David C. Hastings as attorney-in-fact for Frank Torti

Key filing fact

Frank Torti filed Form 4 for Arbutus Biopharma Corp (ABUS) on 24 May 2024.

Key facts

This page summarizes Frank Torti's Form 4 filing for Arbutus Biopharma Corp (ABUS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 May 2024, 16:07.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABUS transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 2 footnotes

Footnote F1

Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

Footnote F2

The option is fully vested and exercisable as of the date of the grant.